{
"METABOLOMICS WORKBENCH":{"STUDY_ID":"ST001120","ANALYSIS_ID":"AN001832","VERSION":"1","CREATED_ON":"January 15, 2019, 9:05 am"},

"PROJECT":{"PROJECT_TITLE":"Lipid Metabolism in Bladder Cancer with Cisplatin Resistance","PROJECT_SUMMARY":"This study conducted comprehensive and comparative lipidomic profiling of two isogenic human T24 bladder cell lines, which are characterized as sensitive or resistant to the cisplatin-induced cell apoptosis.","INSTITUTE":"Cedars-Sinai Medical Center","DEPARTMENT":"Departments of Surgery and Biomedical Sciences","LAST_NAME":"Kim","FIRST_NAME":"Jayoung","ADDRESS":"8700 Beverly Blvd., Davis 5071 Los Angeles, CA 90048, USA","EMAIL":"Jayoung.Kim@cshs.org","PHONE":"310-423-7168"},

"STUDY":{"STUDY_TITLE":"Reprogrammed Lipid Metabolism in Bladder Cancer with Cisplatin Resistance","STUDY_SUMMARY":"This study conducted comprehensive and comparative lipidomic profiling of two isogenic human T24 bladder cell lines, which are characterized as sensitive or resistant to the cisplatin-induced cell apoptosis.","INSTITUTE":"Cedars-Sinai Medical Center","DEPARTMENT":"Departments of Surgery and Biomedical Sciences","LAST_NAME":"Kim","FIRST_NAME":"Jayoung","ADDRESS":"8700 Beverly Blvd., Davis 5071 Los Angeles, CA 90048, USA","EMAIL":"Jayoung.Kim@cshs.org","PHONE":"310-423-7168","STUDY_COMMENTS":"Treatment with ACSS1 inhibitor"},

"SUBJECT":{"SUBJECT_TYPE":"Cell line","SUBJECT_SPECIES":"Homo sapiens","TAXONOMY_ID":"9606"},
"SUBJECT_SAMPLE_FACTORS":[
{
"Subject ID":"-",
"Sample ID":"S-_01",
"Factors":{"Cell line":"T24S","Treatment":"No"}
},
{
"Subject ID":"-",
"Sample ID":"S-_02",
"Factors":{"Cell line":"T24S","Treatment":"No"}
},
{
"Subject ID":"-",
"Sample ID":"S+_01",
"Factors":{"Cell line":"T24S","Treatment":"Yes"}
},
{
"Subject ID":"-",
"Sample ID":"S+_02",
"Factors":{"Cell line":"T24S","Treatment":"Yes"}
},
{
"Subject ID":"-",
"Sample ID":"R-_01",
"Factors":{"Cell line":"T24R","Treatment":"No"}
},
{
"Subject ID":"-",
"Sample ID":"R-_02",
"Factors":{"Cell line":"T24R","Treatment":"No"}
},
{
"Subject ID":"-",
"Sample ID":"R+_01",
"Factors":{"Cell line":"T24R","Treatment":"Yes"}
},
{
"Subject ID":"-",
"Sample ID":"R+_02",
"Factors":{"Cell line":"T24R","Treatment":"Yes"}
}
],
"COLLECTION":{"COLLECTION_SUMMARY":"T24 BC cells were obtained and cultured, according to instructions provided by the ATCC. Media was supplemented with 10% fetal bovine serum, 2% glutamine and 1% antibiotics (Invitrogen, Carlsbad, CA). Cells were maintained under a humidified atmosphere of 5% CO2 at 37°C. These cell lines were negative for mycoplasma and all other infectious agents evaluated.","SAMPLE_TYPE":"Cultured cells"},

"TREATMENT":{"TREATMENT_SUMMARY":"T24 BC cells were characterized in our laboratory as cisplatin resistant BC (T24R, R) or cisplatin sensitive BC cells (T24S, S) to cisplatin-induced apoptosis."},

"SAMPLEPREP":{"SAMPLEPREP_SUMMARY":"We separated lipid extracts from proteins and polar hydrophilic small molecules in a way where the lipids are found in the top layer of liquid-liquid separations, rather than in the bottom layer. Decanting the top layer, therefore, ensured that proteins or polar compounds did not contaminate extracts."},

"CHROMATOGRAPHY":{"CHROMATOGRAPHY_TYPE":"Reversed phase","INSTRUMENT_NAME":"Waters Acquity","COLUMN_NAME":"Waters Acquity CSH C18 (100 x 2.1mm, 1.7um) particles)"},

"ANALYSIS":{"ANALYSIS_TYPE":"MS"},

"MS":{"INSTRUMENT_NAME":"Agilent 6530 QTOF","INSTRUMENT_TYPE":"QTOF","MS_TYPE":"ESI","ION_MODE":"POSITIVE","MS_COMMENTS":"none","MS_RESULTS_FILE":"ST001120_AN001832_Results.txt UNITS:normalized_intensity Has m/z:Yes Has RT:Yes RT units:Minutes"}

}